Karina Knorr

Ismaninger Str. 22
Munich, BY 81675, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Assessment of nephrotoxicity following lutetium-177 PSMA I&T radioligand therapy: a comparative study with docetaxel chemotherapy.

Assessment of nephrotoxicity following lutetium-177 PSMA I&T radioligand therapy: a comparative study with docetaxel chemotherapy.

Journal: European journal of nuclear medicine and molecular imaging

Published: November 13, 2025

Fully automated spleen segmentation predicts progression-free survival in HCC patients following transarterial radioembolization.

Fully automated spleen segmentation predicts progression-free survival in HCC patients following transarterial radioembolization.

Journal: European journal of nuclear medicine and molecular imaging

Published: November 02, 2025

Long-Term Nephrotoxicity of 177Lu-PSMA Radioligand Therapy.

Long-Term Nephrotoxicity of 177Lu-PSMA Radioligand Therapy.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: May 04, 2023

Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of 177Lu-PSMA I&T.

Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of 177Lu-PSMA I&T.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: April 17, 2023

The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy.

The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: December 19, 2022

Safety and Efficacy of [177Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years.

Safety and Efficacy of [177Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: December 06, 2022

177Lu-PSMA-I&T for Treatment of Metastatic Castration-Resistant Prostate Cancer: Prognostic Value of Scintigraphic and Clinical Biomarkers.

177Lu-PSMA-I&T for Treatment of Metastatic Castration-Resistant Prostate Cancer: Prognostic Value of Scintigraphic and Clinical Biomarkers.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: May 11, 2022

Extensive 177Lu-PSMA Radioligand Therapy Can Lead to Radiation Nephropathy with a Renal Thrombotic Microangiopathy-like Picture.

Extensive 177Lu-PSMA Radioligand Therapy Can Lead to Radiation Nephropathy with a Renal Thrombotic Microangiopathy-like Picture.

Journal: European urology

Published: February 08, 2022

Utility of 18F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology.

Utility of 18F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: October 26, 2021

18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study.

18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: July 07, 2021

Positron emission tomography with computed tomography/magnetic resonance imaging for primary staging of prostate cancer

Positron emission tomography with computed tomography/magnetic resonance imaging for primary staging of prostate cancer

Journal: Der Radiologe

Published: July 06, 2021

Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3.

Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3.

Journal: EJNMMI research

Published: July 02, 2021

Showing 1-12 of 22

Last Updated: 09/26/2026